Booth Bruce's Form 4 filing
Kymera Therapeutics, Inc. (KYMR) · filed Mar 13, 2024
- Accession no.
- 0001415889-24-007890
- Filed
- Mar 13, 2024
- Trade date
- Mar 11-13, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 12 non-derivative transactions. Open-market sales total $14.9M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Booth BruceCIK 0001451612 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 11, 2024 | Common Stock | SSaleDisposed | −37,180 | $42.77F2 | −$1,590,188.6 | 4,930,934 | Indirect | |
| Mar 11, 2024 | Common Stock | SSaleDisposed | −5,122 | $43.42F4 | −$222,397.24 | 4,925,812 | Indirect | |
| Mar 11, 2024 | Common Stock | SSaleDisposed | −7,837 | $42.77F2 | −$335,188.49 | 882,311 | Indirect | |
| Mar 11, 2024 | Common Stock | SSaleDisposed | −1,045 | $43.42F4 | −$45,373.9 | 881,266 | Indirect | |
| Mar 12, 2024 | Common Stock | SSaleDisposed | −126,066 | $41.94F7 | −$5,287,208.04 | 4,799,746 | Indirect | |
| Mar 12, 2024 | Common Stock | SSaleDisposed | −8,581 | $42.52F8 | −$364,864.12 | 4,791,165 | Indirect | |
| Mar 12, 2024 | Common Stock | SSaleDisposed | −26,452 | $41.94F7 | −$1,109,396.88 | 854,814 | Indirect | |
| Mar 12, 2024 | Common Stock | SSaleDisposed | −1,819 | $42.52F8 | −$77,343.88 | 852,995 | Indirect | |
| Mar 13, 2024 | Common Stock | SSaleDisposed | −108,404 | $42.19F9 | −$4,573,564.76 | 4,682,761 | Indirect | |
| Mar 13, 2024 | Common Stock | SSaleDisposed | −6,686 | $42.84F10 | −$286,428.24 | 4,676,075 | Indirect | |
| Mar 13, 2024 | Common Stock | SSaleDisposed | −22,779 | $42.19F9 | −$961,046.01 | 830,216 | Indirect | |
| Mar 13, 2024 | Common Stock | SSaleDisposed | −1,386 | $42.84F10 | −$59,376.24 | 828,830 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.1826 to $43.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7), (8), (9) and (10).
Referenced by the price of 2 transactions in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.185 to $44.03 inclusive.
Referenced by the price of 2 transactions in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.445 to $42.43 inclusive.
Referenced by the price of 2 transactions in Table I.
- F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.46 to $42.90 inclusive.
Referenced by the price of 2 transactions in Table I.
- F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $42.475 inclusive.
Referenced by the price of 2 transactions in Table I.
- F10
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6032 to $43.0839 inclusive.
Referenced by the price of 2 transactions in Table I.